Literature DB >> 30017879

Oncolytic Virotherapy: Single Cycle Cures or Repeat Treatments? (Repeat Dosing Is Crucial!).

Alan Melcher1.   

Abstract

Mesh：

Year:  2018        PMID： 30017879      PMCID： PMC6094867          DOI： 10.1016/j.ymthe.2018.07.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

Review 2.  Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

Authors:  Shashi Gujar; Jonathan G Pol; Youra Kim; Patrick W Lee; Guido Kroemer
Journal:  Trends Immunol       Date:  2017-12-20       Impact factor: 16.687

3.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Authors:  Adel Samson; Karen J Scott; David Taggart; Emma J West; Erica Wilson; Gerard J Nuovo; Simon Thomson; Robert Corns; Ryan K Mathew; Martin J Fuller; Timothy J Kottke; Jill M Thompson; Elizabeth J Ilett; Julia V Cockle; Philip van Hille; Gnanamurthy Sivakumar; Euan S Polson; Samantha J Turnbull; Elizabeth S Appleton; Gemma Migneco; Ailsa S Rose; Matthew C Coffey; Deborah A Beirne; Fiona J Collinson; Christy Ralph; D Alan Anthoney; Christopher J Twelves; Andrew J Furness; Sergio A Quezada; Heiko Wurdak; Fiona Errington-Mais; Hardev Pandha; Kevin J Harrington; Peter J Selby; Richard G Vile; Stephen D Griffin; Lucy F Stead; Susan C Short; Alan A Melcher
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

4.  Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Authors:  Robert A Adair; Victoria Roulstone; Karen J Scott; Ruth Morgan; Gerard J Nuovo; Martin Fuller; Deborah Beirne; Emma J West; Victoria A Jennings; Ailsa Rose; Joan Kyula; Sheila Fraser; Rajiv Dave; David A Anthoney; Alison Merrick; Robin Prestwich; Amer Aldouri; Oliver Donnelly; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Giles Toogood; Kevin Harrington; Alan A Melcher
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

Review 5.  Tolerance, danger, and the extended family.

Authors:  P Matzinger
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.

Authors:  F K Eshun; M A Currier; R A Gillespie; J L Fitzpatrick; W H Baird; T P Cripe
Journal:  Gene Ther       Date:  2010-05-27       Impact factor: 5.250

7.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

8.  Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.

Authors:  David P Conrad; Jovian Tsang; Meaghan Maclean; Jean-Simon Diallo; Fabrice Le Boeuf; Chantal G Lemay; Theresa J Falls; Kelley A Parato; John C Bell; Harold L Atkins
Journal:  Clin Cancer Res       Date:  2013-05-28       Impact factor: 12.531

9.  Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Authors:  Elizabeth Ilett; Timothy Kottke; Oliver Donnelly; Jill Thompson; Candice Willmon; Rosa Diaz; Shane Zaidi; Matt Coffey; Peter Selby; Kevin Harrington; Hardev Pandha; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2014-06-24       Impact factor: 11.454

10.  Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Authors:  Jacob M Ricca; Anton Oseledchyk; Tyler Walther; Cailian Liu; Levi Mangarin; Taha Merghoub; Jedd D Wolchok; Dmitriy Zamarin
Journal:  Mol Ther       Date:  2018-01-31       Impact factor: 11.454
View more
  1 in total

1.  The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress.

Authors:  Jinqiong Jiang; Weida Wang; Weineng Xiang; Lin Jiang; Qian Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.